Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TQC3721 inhalation powder in moderate to severe COPD
ChiCTR2500112449Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQC3721 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Change in maximum FEV1. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
TQC3721
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2500112449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112449.